HRP20171202T1 - Nove molekule jnk inhibitora - Google Patents
Nove molekule jnk inhibitora Download PDFInfo
- Publication number
- HRP20171202T1 HRP20171202T1 HRP20171202TT HRP20171202T HRP20171202T1 HR P20171202 T1 HRP20171202 T1 HR P20171202T1 HR P20171202T T HRP20171202T T HR P20171202TT HR P20171202 T HRP20171202 T HR P20171202T HR P20171202 T1 HRP20171202 T1 HR P20171202T1
- Authority
- HR
- Croatia
- Prior art keywords
- jnk inhibitor
- sequence
- seq
- amino acid
- antibody
- Prior art date
Links
- 229940118135 JNK inhibitor Drugs 0.000 title claims 28
- 239000012825 JNK inhibitor Substances 0.000 title claims 28
- 229940024606 amino acid Drugs 0.000 claims 16
- 235000001014 amino acid Nutrition 0.000 claims 16
- 150000001413 amino acids Chemical group 0.000 claims 16
- 238000000034 method Methods 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 108010078791 Carrier Proteins Proteins 0.000 claims 5
- 150000008574 D-amino acids Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- 241000283707 Capra Species 0.000 claims 3
- 150000008575 L-amino acids Chemical group 0.000 claims 3
- 241000699666 Mus <mouse, genus> Species 0.000 claims 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 3
- 241000700159 Rattus Species 0.000 claims 3
- 230000003053 immunization Effects 0.000 claims 3
- 238000002649 immunization Methods 0.000 claims 3
- 230000016784 immunoglobulin production Effects 0.000 claims 3
- 238000002955 isolation Methods 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 2
- 229930064664 L-arginine Natural products 0.000 claims 2
- 235000014852 L-arginine Nutrition 0.000 claims 2
- 235000019454 L-leucine Nutrition 0.000 claims 2
- 239000004395 L-leucine Substances 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 229960003136 leucine Drugs 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000012228 culture supernatant Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (25)
1. JNK inhibitor koji sadrži inhibirajuću peptidnu sekvencu prema sljedećoj općoj formuli
X1-X2-X3-R-X4-X5-X6-L-X7-L-X8 (SEQ ID NO: 1),
pri čemu X1 je amino kiselina koja se bira od amino kiselina R, P i Q,
pri čemu X2 je amino kiselina koja se bira od amino kiselina R, P i G,
pri čemu X3 je amino kiselina koja se bira od amino kiselina K, R, k i r,
pri čemu X4 je amino kiselina koja se bira od amino kiselina P i K,
pri čemu X5 je amino kiselina koja se bira od amino kiselina T, a, s, q, k ili je odsutan, pri čemu X6 je amino kiselina koja se bira od amino kiselina T, D i A,
pri čemu X7 je amino kiselina koja se bira od amino kiselina N, n, r i K; i
pri čemu X8 je amino kiselina koja se bira od F, f i w, te
pri čemu aminokiselinski ostatak naveden velikim slovima označava ostatak L-amino kiseline, dok aminokiselinski ostatak naveden malim slovima označava ostatak D-amino kiseline,
pod uvjetom da je/su barem jedna od amino kiselina odabrana iz skupine koja sadrži X3, X5, X7 i X8 D-amino kiselinu(e).
2. JNK inhibitor prema zahtjevu 1, naznačen time da je inhibirajuća peptidna sekvenca odabrana iz bilo koje od SEQ ID NOs: 3-20, 22-24 i 27.
3. JNK inhibitor prema zahtjevu 1 ili 2, naznačen time da JNK inhibitor sadrži inhibirajuću peptidnu sekvencu koja dijeli barem 80% identičnosti sekvence sa sekvencom odabranom iz bilo koje od SEQ ID NOs: 3-20, 22-24 i 27.
4. JNK inhibitor prema bilo kojem od prethodnih zahtjeva, naznačen time da JNK inhibitor sadrži SEQ ID NO: 8 ili inhibirajuću peptidnu sekvencu koja dijeli barem 80% identičnosti sekvence sa SEQ ID NO: 8.
5. JNK inhibitor prema bilo kojem od prethodnih zahtjeva, naznačen time da JNK inhibitor sadrži transporter sekvencu.
6. JNK inhibitor prema zahtjevu 5, naznačen time da se inhibirajuća peptidna sekvenca i transporter sekvenca preklapaju.
7. JNK inhibitor prema zahtjevu 5 ili 6, naznačen time da transporter sekvenca sadrži sekvencu naizmjeničnih D- i L-amino kiselina prema bilo kojoj od SEQ ID NOs: 28-30, ili transporter sekvencu odabranu iz bilo koje od SEQ ID NOs: 31-170.
8. JNK inhibitor prema bilo kojem od zahtjeva 5 ili 7, naznačen time da je navedena transporter sekvenca smještena izravno na N-terminalnom kraju ili izravno na C-terminalnom kraju inhibirajuće peptidne sekvence.
9. JNK inhibitor prema bilo kojem od zahtjeva 5-8, naznačen time da JNK inhibitor sadrži
a) sekvencu prema bilo kojoj od SEQ ID NOs: 171-183, 185-187 ili 190 ili
b) sekvencu koja dijeli barem 50% identičnosti sekvence sa barem jednom od SEQ ID NOs: 171-190, pod uvjetom da navedena sekvenca dijeli identičnost sekvence sa bilo kojom od SEQ ID NOs: 171-190:
i) održava ostatak L-arginin (R) na položaju 4 u njegovom odsječku sekvence koji odgovara SEQ ID NO: 1,
ii) održava dva ostatka L-leucin (L) u njihovom odsječku sekvence koji odgovara SEQ ID NO: 1, i
iii) ima barem jednu D-amino kiselinu na položajima X3, X5, X7 ili X8 u njegovom odsječku sekvence koji odgovara SEQ ID NO: 1.
10. JNK inhibitor prema zahtjevu 9, naznačen time da JNK inhibitor sadrži
a) sekvencu prema SEQ ID NO: 172 ili
b) sekvencu koja dijeli barem 50% identičnosti sekvence sa SEQ ID NO: 172, pod uvjetom da navedena sekvenca koja dijeli identičnosti sekvence sa SEQ ID NO: 172:
i) održava ostatak L-arginin (R) na položaju 4 u njegovom odsječku sekvence koji odgovara SEQ ID NO: 1,
ii) održava dva ostatka L-leucin (L) u njihovom odsječku sekvence koji odgovara SEQ ID NO: 1, i
iii) ima barem jednu D-amino kiselinu na položajima X3, X5, X7 ili X8 u njegovom odsječku sekvence koji odgovara SEQ ID NO: 1.
11. JNK inhibitor prema zahtjevu 10, naznačen time da JNK inhibitor obuhvaća sekvencu prema SEQ ID NO: 172.
12. Postupak ne-terapeutskog imuniziranja neljudske životinje s JNK inhibitorom prema bilo kojem od zahtjeva 1-11, naznačen time da postupak obuhvaća slijedeći korak:
- ne-terapeutsko dovođenje u kontakt neljudske životinje pogodne za proizvodnju protutijela s JNK inhibitorom prema bilo kojem od zahtjeva 1-11.
13. Postupak ne-terapeutskog imuniziranja neljudske životinje prema zahtjevu 12, naznačen time da neljudska životinja je sisavac koji nije čovjek.
14. Postupak ne-terapeutskog imuniziranja neljudske životinje prema zahtjevu 13, naznačen time da je neljudska životinja odabrana od koze, miša, štakora i zeca.
15. Postupak za proizvodnju protutijela koje prepoznaje JNK inhibitor prema bilo kojem od zahtjeva 1-11, naznačen time da postupak obuhvaća korak:
- izoliranja protutijela koje prepoznaje navedeni JNK inhibitor iz neljudske životinje prikladne za proizvodnju protutijela, koja je bila u prethodnom ne-terapeutskom kontaktu s JNK inhibitorom prema bilo kojem od zahtjeva 1-11.
16. Postupak za proizvodnju protutijela prema zahtjevu 15, naznačen time da neljudska životinja je sisavac koji nije čovjek.
17. Postupak za proizvodnju protutijela prema zahtjevu 16, naznačen time da neljudska životinja je odabrana od koze, miša, štakora i zeca.
18. Postupak izoliranja stanice koja proizvodi protutijelo koje prepoznaje JNK inhibitor prema bilo kojem od zahtjeva 1-11, naznačen time da postupak obuhvaća korak:
- izoliranja, iz neljudske životinje prikladne za proizvodnju protutijela, koja je bila u prethodnom ne-terapeutskom kontaktu s JNK inhibitorom prema bilo kojem od zahtjeva 1-11, stanice koja proizvodi navedeno protutijelo koje prepoznaje navedeni JNK inhibitor.
19. Postupak izoliranja stanice prema zahtjevu 18, naznačen time da neljudska životinja je sisavac koji nije čovjek.
20. Postupak izoliranja stanice prema zahtjevu 19, naznačen time da je neljudska životinja odabrana od koze, miša, štakora i zeca
21. Postupak izoliranja stanice prema bilo kojem od zahtjeva 18 - 20, naznačen time da stanica koja proizvodi navedeno protutijelo je imortalizirana.
22. Postupak za proizvodnju protutijela koje specifično prepoznaje JNK inhibitor prema bilo kojem od zahtjeva 1-11, naznačen time da postupak obuhvaća korak:
izoliranja protutijela koje specifično prepoznaje JNK inhibitor prema bilo kojem od zahtjeva 1-11, iz supernatanta stanične kulture od stanice koja proizvodi navedeno protutijelo.
23. Postupak za proizvodnju protutijela prema zahtjevu 22, naznačen time da stanica koja proizvodi navedeno protutijelo je imortalizirana.
24. Protutijelo koje se može proizvesti s bilo kojim od postupaka prema bilo kojem od zahtjeva 15 - 17 ili 22 - 23, naznačeno time da protutijelo prepoznaje barem jedan peptid odabran iz bilo koje od SEQ ID NOs: 1, 3-20, 22-24 i 27, ali ne prepoznaje uglavnom iste peptide s L-amino kiselinama na mjestu D-amino kiselina.
25. Stanica koja se može proizvesti postupkom prema bilo kojem od zahtjeva 18-21, naznačena time da stanica proizvodi protutijelo prema zahtjevu 24.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/003729 WO2011160653A1 (en) | 2010-06-21 | 2010-06-21 | Novel jnk inhibitor molecules |
| PCT/EP2011/003074 WO2011160827A2 (en) | 2010-06-21 | 2011-06-21 | Novel jnk inhibitor molecules |
| EP11727401.9A EP2582714B1 (en) | 2010-06-21 | 2011-06-21 | Novel jnk inhibitor molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171202T1 true HRP20171202T1 (hr) | 2017-10-06 |
Family
ID=43413497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171202TT HRP20171202T1 (hr) | 2010-06-21 | 2017-08-07 | Nove molekule jnk inhibitora |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8981052B2 (hr) |
| EP (2) | EP2582714B1 (hr) |
| JP (2) | JP5926250B2 (hr) |
| KR (1) | KR20130037218A (hr) |
| CN (2) | CN103025754B (hr) |
| AU (1) | AU2011269329B2 (hr) |
| BR (1) | BR112012032738A2 (hr) |
| CA (1) | CA2798100C (hr) |
| CY (1) | CY1119173T1 (hr) |
| DK (1) | DK2582714T3 (hr) |
| ES (2) | ES2637277T3 (hr) |
| HK (1) | HK1222181A1 (hr) |
| HR (1) | HRP20171202T1 (hr) |
| HU (1) | HUE033828T2 (hr) |
| IL (1) | IL223136A0 (hr) |
| LT (1) | LT2582714T (hr) |
| MX (1) | MX337203B (hr) |
| PL (2) | PL2993180T3 (hr) |
| PT (1) | PT2582714T (hr) |
| RU (1) | RU2570417C2 (hr) |
| SG (2) | SG185495A1 (hr) |
| SI (1) | SI2582714T1 (hr) |
| WO (2) | WO2011160653A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| WO2012048721A1 (en) | 2010-10-14 | 2012-04-19 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| WO2013091670A1 (en) * | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| WO2014206426A1 (en) * | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2015197097A1 (en) * | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| JP2016523274A (ja) * | 2013-06-26 | 2016-08-08 | ザイジェン インフラメーション リミテッド | 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用 |
| EP3160989A2 (en) * | 2014-06-26 | 2017-05-03 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| WO2018029336A1 (en) | 2016-08-12 | 2018-02-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway. |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1195304B (it) | 1981-12-22 | 1988-10-12 | Anic Spa | Metodo per la preparazione di gem-diammino derivati n-monoacilati |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
| IT1190389B (it) | 1985-09-19 | 1988-02-16 | Eniricerche Spa | Esapeptidi ad attivita' ipotensiva |
| US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| IT1227907B (it) | 1988-12-23 | 1991-05-14 | Eniricerche S P A Milano Sclav | Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento |
| US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5652122A (en) | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
| US5840313A (en) | 1990-09-27 | 1998-11-24 | Syntello Vaccine Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
| AU1753892A (en) | 1991-04-10 | 1992-11-17 | General Hospital Corporation, The | Mammalian gap-43 compositions and methods of use |
| US5350835A (en) | 1991-11-05 | 1994-09-27 | Board Of Regents, University Of Texas | Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids |
| US5994108A (en) | 1991-11-05 | 1999-11-30 | Board Of Regents, The University Of Texas System | Mutant TAR virus and transdominant tat mutants as pharmacological agents |
| EP0632722A4 (en) | 1992-03-20 | 1997-07-30 | Baylor College Medicine | DNA TRANSPORTATION SYSTEM AND INSTRUCTIONS FOR USE. |
| EP1236473A3 (en) | 1992-04-03 | 2003-01-15 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
| WO1994004562A1 (en) | 1992-08-13 | 1994-03-03 | The General Hospital Corporation | Mammalian gap-43 compositions and methods of use |
| NZ255831A (en) | 1992-08-21 | 1997-04-24 | Biogen Inc | Fusion proteins comprising biologically active cargo moiety and transport peptides from the hiv tat protein, their preparation and use |
| BR9306984A (pt) | 1992-08-27 | 1999-01-12 | Deakin Res Ltd | Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo |
| US5545551A (en) | 1992-08-28 | 1996-08-13 | Mt. Sinai School Of Medicine Of The City University Of New York | Cloning and expression of pur protein |
| WO1994023751A1 (de) | 1993-04-14 | 1994-10-27 | Boehringer Mannheim Gmbh | Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen |
| CA2153480A1 (en) | 1993-11-12 | 1995-06-01 | Kenichi Matsubara | Gene signature |
| US5807746A (en) | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
| CA2193354A1 (en) | 1995-04-25 | 1996-10-31 | Catherine Lee | Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells |
| EP0845043B1 (en) | 1995-07-28 | 2007-06-27 | Marie Curie Cancer Care | Transport proteins and their uses |
| WO1997010836A1 (en) | 1995-09-21 | 1997-03-27 | Innapharma, Inc. | Peptides and peptidomimetics inhibiting the oncogenic action of p21 ras |
| IE80466B1 (en) | 1995-11-10 | 1998-07-29 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| US5877282A (en) | 1996-09-20 | 1999-03-02 | Bristol-Myers Squibb Company | Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |
| US6187817B1 (en) | 1996-10-03 | 2001-02-13 | Southern Illinois University School Of Medicine | Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds |
| US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| AU7410998A (en) | 1996-11-26 | 1998-06-22 | Johns Hopkins University, The | Ligand detection system and methods of use thereof |
| US5989814A (en) | 1997-04-01 | 1999-11-23 | Reagents Of The University Of California | Screening methods in eucaryotic cells |
| US5880261A (en) | 1997-04-03 | 1999-03-09 | Waeber; Gerard | Transcription factor Islet-Brain 1 (IB1) |
| WO1998047913A2 (en) | 1997-04-18 | 1998-10-29 | The University Of Medicine And Dentistry Of New Jersey | Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog |
| US6043083A (en) | 1997-04-28 | 2000-03-28 | Davis; Roger J. | Inhibitors of the JNK signal transduction pathway and methods of use |
| JP4129298B2 (ja) | 1997-05-15 | 2008-08-06 | サイトジェン コーポレーション | 胃腸管（ｇｉｔ）輸送受容体に結合するランダムペプチド、及び関連した方法 |
| US20040152084A1 (en) | 2003-01-31 | 2004-08-05 | Slattum Paul M. | Compounds and processes for single-pot attachment of a label to nucleic acid |
| EP0975370B9 (en) | 1997-05-21 | 2004-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| FR2767323B1 (fr) | 1997-08-12 | 2001-01-05 | Synt Em | Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives |
| EP0897002A3 (en) | 1997-08-14 | 2001-10-04 | Smithkline Beecham Plc | U62317, a protein having a JNK-binding domain |
| WO1999016787A1 (en) | 1997-09-26 | 1999-04-08 | Washington University | Cell death agonists |
| US6420031B1 (en) | 1997-11-03 | 2002-07-16 | The Trustees Of Princeton University | Highly transparent non-metallic cathodes |
| PL340412A1 (en) | 1997-10-20 | 2001-01-29 | Hoffmann La Roche | Bicyclic kinase inhibitors |
| US6270956B1 (en) | 1997-12-11 | 2001-08-07 | The Salk Institute For Biological Studies | Transcriptional coactivator that interacts with Tat protein and regulates its binding to TAR RNA, methods for modulating Tat transactivation, and uses therefor |
| EP0947524A1 (en) | 1998-03-30 | 1999-10-06 | Upither B.V. | Novel peptides for the treatment of autoimmune diseases |
| US6248558B1 (en) | 1998-03-31 | 2001-06-19 | Vanderbilt University | Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
| CA2330458A1 (en) | 1998-04-29 | 1999-11-04 | Georgetown University | Methods of identifying and using hla binding compounds as hla-agonists and antagonists |
| CA2327354A1 (en) | 1998-05-13 | 1999-11-18 | Incyte Pharmaceuticals, Inc. | Human apoptosis associated proteins |
| US6811992B1 (en) | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
| AU3714499A (en) | 1998-05-14 | 1999-11-29 | Pasteur Merieux Serums Et Vaccins | Hepatitis c virus mimotopes |
| CA2331384A1 (en) * | 1998-06-18 | 1999-12-23 | Dnavec Research Inc. | Nucleic acid transfer phage |
| US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| AU755564B2 (en) | 1998-06-20 | 2002-12-12 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| DK1400551T3 (da) | 1998-08-28 | 2007-10-15 | Amylin Pharmaceuticals Inc | Polyamidkæder med præcis længde og deres konjugater med proteiner |
| CN1329034C (zh) | 1998-09-25 | 2007-08-01 | 赛福伦公司 | 预防/治疗感觉毛细胞和耳蜗神经元损伤的药物 |
| US6656474B1 (en) | 1999-01-15 | 2003-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
| US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| EP1181306A4 (en) | 1999-05-28 | 2003-06-18 | Apoptosis Technology Inc | COMPOUNDS AND METHODS FOR REGULATING APOPTOSIS, AND METHODS OF MAKING AND SCREENING REGULATORY COMPOUNDS FOR APOPTOSIS |
| US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| AU5316900A (en) | 1999-06-03 | 2000-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) |
| WO2000075164A1 (en) | 1999-06-07 | 2000-12-14 | Mirus Corporation | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| EP1210121A2 (en) | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| US20030104622A1 (en) | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
| US6881825B1 (en) | 1999-09-01 | 2005-04-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues |
| US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US6610820B1 (en) | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US20030108539A1 (en) | 2000-02-14 | 2003-06-12 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| IL149933A0 (en) | 1999-12-06 | 2002-11-10 | Gen Hospital Corp | Pancreatic stem cells and their use in transplantation |
| US6586403B1 (en) | 2000-07-20 | 2003-07-01 | Salpep Biotechnology, Inc. | Treating allergic reactions and inflammatory responses with tri-and dipeptides |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| JP4387669B2 (ja) | 2000-10-13 | 2009-12-16 | ザイジェン エス．アー． | 新規なトランスポーターペプチド配列による生物学的エフェクターの細胞内送達 |
| US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
| EP1333846B1 (en) | 2000-10-17 | 2012-04-18 | Diabcell Pty Limited | Preparation and xenotransplantation or porcine islets |
| US7199124B2 (en) | 2001-02-02 | 2007-04-03 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
| US20030077826A1 (en) | 2001-02-02 | 2003-04-24 | Lena Edelman | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
| US20030091640A1 (en) | 2001-02-08 | 2003-05-15 | Srinivasan Ramanathan | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents |
| DE60233137D1 (de) | 2001-02-16 | 2009-09-10 | Univ R | Transporter mit beabstandeten arginin-teilchen |
| DE60215626T2 (de) | 2001-04-06 | 2007-08-30 | Thomas Jefferson University | Antagonist für die multimerisierung von hiv-1 vif-protein |
| DE10117281A1 (de) | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
| AU2002322519A1 (en) | 2001-07-17 | 2003-03-03 | Incyte Genomics, Inc. | Proteins associated with cell growth, differentiation, and death |
| CN100391958C (zh) | 2001-09-19 | 2008-06-04 | 安万特医药股份有限公司 | 化合物 |
| US7635681B2 (en) | 2002-01-09 | 2009-12-22 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US7351729B2 (en) | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| US20040171809A1 (en) | 2002-09-09 | 2004-09-02 | Korsmeyer Stanley J. | BH3 peptides and method of use thereof |
| MXPA05003063A (es) | 2002-09-20 | 2005-05-27 | Alcon Inc | Uso de inhibidores de la sintesis de citosina para el tratamiento de trastornos de ojos secos. |
| DK1408114T3 (da) | 2002-10-11 | 2007-05-07 | Imvision Gmbh | Modulære antigen-transporter molekyler (MAT-molekyler) til modulation af immunreaktioner, tilhörende konstrukter, fremgangsmåder og anvendelser |
| US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
| AU2003286611A1 (en) | 2002-10-24 | 2004-05-13 | Sangstat Medical Corporation | Cytomodulating peptides and methods for treating neurological disorders |
| EP1578365A4 (en) | 2002-11-14 | 2009-09-23 | Arbor Vita Corp | MOLECULAR INTERACTIONS IN NEURONS |
| MXPA05005161A (es) | 2002-11-18 | 2005-07-22 | Celgene Corp | Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida. |
| US20050019366A1 (en) | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
| US7166692B2 (en) | 2003-03-04 | 2007-01-23 | Canbrex Bio Science Walkersville, Inc. | Intracellular delivery of small molecules, proteins, and nucleic acids |
| US7432375B2 (en) | 2003-03-06 | 2008-10-07 | Eisai R & D Management Co., Ltd. | JNK inhibitors |
| US20080090770A1 (en) | 2003-04-11 | 2008-04-17 | Belmares Michael P | Modulation of Muc1 Mediated Signal Transduction |
| DK2351844T3 (da) | 2003-04-29 | 2014-09-22 | Sarepta Therapeutics Inc | Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler |
| WO2005084158A2 (en) | 2003-06-20 | 2005-09-15 | The Regents Of The University Of California | Polypeptide transduction and fusogenic peptides |
| KR100685345B1 (ko) | 2004-03-27 | 2007-02-22 | 학교법인조선대학교 | 세포사 유도 펩타이드 |
| CN1960726A (zh) | 2004-04-08 | 2007-05-09 | 应用研究系统Ars股份公司 | 包含jnk抑制剂和环孢菌素的组合物 |
| US20080187575A1 (en) | 2004-08-27 | 2008-08-07 | Bert Klebl | Pyrimidine Derivatives |
| US20060094753A1 (en) | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
| EP1656951A1 (en) | 2004-11-12 | 2006-05-17 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
| US20060258706A1 (en) | 2005-04-29 | 2006-11-16 | Manohar Saindane | Solid forms of a JNK inhibitor |
| US20070015779A1 (en) | 2005-04-29 | 2007-01-18 | John Griffin | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| US20070003531A1 (en) | 2005-06-30 | 2007-01-04 | University Of Connecticut | Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes |
| US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| US10045953B2 (en) | 2006-07-06 | 2018-08-14 | Case Western Reserve University | Ceramide composition and method of use |
| WO2008094208A2 (en) | 2006-08-02 | 2008-08-07 | Northwestern University | Protein kinase targeted therapeutics |
| BRPI0717035B8 (pt) | 2006-09-08 | 2021-05-25 | Hoffmann La Roche | moduladores de benzotriazol cinase |
| GB0702259D0 (en) | 2007-02-06 | 2007-03-14 | Eisai London Res Lab Ltd | 7-azaindole derivatives |
| PT2285364E (pt) | 2008-05-07 | 2015-02-24 | Univ California | Reposição e enriquecimento terapêutico de lubrificação da superficie ocular |
| WO2009143865A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| US20100183633A1 (en) | 2008-12-04 | 2010-07-22 | University Of Massachusetts | Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition |
| WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| BRPI1007923A2 (pt) | 2009-02-06 | 2020-08-25 | Elan Pharmaceuticals, Inc | composto, composição farmacêutica, métodos para tratar uma doença neurodegenerativa, e para reduzir a concentração de p-cjun em tecido cerebral de um indivíduo em necessidade do mesmo, uso de um composto, e, método in vitro |
| WO2010113753A1 (ja) | 2009-03-30 | 2010-10-07 | 参天製薬株式会社 | ＪＮＫ（ｃ－Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用 |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| WO2012048721A1 (en) | 2010-10-14 | 2012-04-19 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| WO2012048893A1 (en) | 2010-10-14 | 2012-04-19 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| US8471027B2 (en) | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| WO2014206426A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| EP3160989A2 (en) | 2014-06-26 | 2017-05-03 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
-
2010
- 2010-06-21 WO PCT/EP2010/003729 patent/WO2011160653A1/en active Application Filing
-
2011
- 2011-06-21 PT PT117274019T patent/PT2582714T/pt unknown
- 2011-06-21 WO PCT/EP2011/003074 patent/WO2011160827A2/en active Application Filing
- 2011-06-21 PL PL15002211T patent/PL2993180T3/pl unknown
- 2011-06-21 HU HUE11727401A patent/HUE033828T2/en unknown
- 2011-06-21 EP EP11727401.9A patent/EP2582714B1/en active Active
- 2011-06-21 KR KR1020137001489A patent/KR20130037218A/ko not_active Application Discontinuation
- 2011-06-21 CN CN201180030452.9A patent/CN103025754B/zh active Active
- 2011-06-21 SG SG2012082616A patent/SG185495A1/en unknown
- 2011-06-21 SI SI201131265T patent/SI2582714T1/sl unknown
- 2011-06-21 DK DK11727401.9T patent/DK2582714T3/en active
- 2011-06-21 CA CA2798100A patent/CA2798100C/en active Active
- 2011-06-21 PL PL11727401T patent/PL2582714T3/pl unknown
- 2011-06-21 CN CN201610489532.5A patent/CN106117314A/zh active Pending
- 2011-06-21 SG SG10201507857WA patent/SG10201507857WA/en unknown
- 2011-06-21 ES ES11727401.9T patent/ES2637277T3/es active Active
- 2011-06-21 JP JP2013515767A patent/JP5926250B2/ja active Active
- 2011-06-21 US US13/805,758 patent/US8981052B2/en active Active
- 2011-06-21 EP EP15002211.9A patent/EP2993180B1/en active Active
- 2011-06-21 LT LTEP11727401.9T patent/LT2582714T/lt unknown
- 2011-06-21 MX MX2012014595A patent/MX337203B/es active IP Right Grant
- 2011-06-21 BR BR112012032738A patent/BR112012032738A2/pt not_active IP Right Cessation
- 2011-06-21 ES ES15002211T patent/ES2782381T3/es active Active
- 2011-06-21 RU RU2013102345/04A patent/RU2570417C2/ru not_active IP Right Cessation
- 2011-06-21 AU AU2011269329A patent/AU2011269329B2/en not_active Ceased
-
2012
- 2012-11-19 IL IL223136A patent/IL223136A0/en unknown
-
2015
- 2015-02-04 US US14/614,337 patent/US9624267B2/en active Active
-
2016
- 2016-04-21 JP JP2016085549A patent/JP2017008026A/ja not_active Withdrawn
- 2016-08-30 HK HK16110297.1A patent/HK1222181A1/zh unknown
-
2017
- 2017-07-24 CY CY20171100788T patent/CY1119173T1/el unknown
- 2017-08-07 HR HRP20171202TT patent/HRP20171202T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171202T1 (hr) | Nove molekule jnk inhibitora | |
| RU2013128895A (ru) | Улучшенные n-терминальные кэппинг модули для сконструированных белков с анкириновым повтором | |
| MX347291B (es) | Inmunoglobulinas portadoras y usos de las mismas. | |
| NZ593833A (en) | Extended recombinant polypeptides and compositions comprising same | |
| RU2020106752A (ru) | Субстраты матриксной металлопротеиназы и другие расщепляемые фрагменты и способы их использования | |
| HRP20161315T1 (hr) | Postupak za proizvodnju degareliksa i njegovih međuprodukata | |
| EA201100038A1 (ru) | Коагонисты глюкагонового рецептора/glp-1-рецептора | |
| NZ598356A (en) | Antigenic tau peptides and uses thereof | |
| JP2005120106A5 (hr) | ||
| ES2723774T3 (es) | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal | |
| UA110599C2 (uk) | Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку | |
| MX2011008759A (es) | Medios y metodos para fabricar neurotoxina altamente pura. | |
| NZ591612A (en) | Prevention, treatment and diagnosis of p.gingivalis infection with peptides | |
| DK1819816T3 (da) | Fremgangsmåder til fremstilling og udskillelse af modificerede peptider | |
| EA201001881A1 (ru) | Пролинспецифичная протеаза из penicillium chrysogenum | |
| WO2007039231A3 (en) | Method of producing a modified (poly)peptide | |
| JP2015524403A5 (hr) | ||
| NZ586074A (en) | LCLRP peptides, constructs and uses thereof | |
| CN103588863A (zh) | Rgd环肽合成制备工艺 | |
| RU2014144881A (ru) | Способ экспрессии полипептидов с применением модифицированных нуклеиновых кислот | |
| RU2017122029A (ru) | Новые способы опосредованного ферментами конъюгирования полипептидов с использованием сортазы | |
| HRP20190544T1 (hr) | Ciklični analozi apelina | |
| Rao et al. | Soluble expression and purification of the recombinant bioactive peptide precursor BPP-1 in Escherichia coli using a cELP-SUMO dual fusion system | |
| WO2008113970A3 (en) | Peptides | |
| NZ591133A (en) | Novel melanoma antigen peptide and uses thereof |